Kornimate/medical-research-clean huggingface dataset:
eldertree via a voice activated device for managing chronic health conditions (nhlbi)

Conditions: Chronic Conditions, Multiple

Summary: multiple chronic conditions (mccs) are costly and pervasive among older adults. mccs account for 90% of medicare spending, and 65% of medicare beneficiaries have 3 or more chronic conditions; 23% have 5 or more. mccs are often addressed in primary care, where time pressures force a focus on medication and lab results rather than self-management skills. patients often struggle with treatment adherence and the emotional and physical burdens of self-management and health tracking. chronic conditions reduce quality of life (qol) and increase loneliness, which exacerbate those conditions. the primary purpose of this study is to investigate whether a voice-based platform is better for delivering an electronic health intervention to older adults than a text/typing-based platform. we have an evidence-based electronic health intervention (elder tree, et) that has been shown to improve quality of life, physical and socio-emotional health outcomes for older adults with multiple chronic conditions when delivered via a text/typing-based system. the current project would test whether such patients would benefit even more if et were delivered via a voice-based system (vs. the text-based system) because they would use it more consistently. et is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.


Eligibility criteria:
inclusion criteria: * be ≥60 years old; * have medical record diagnoses of at least 5 chronic conditions of which at least 3 must come from the following: hypertension, hyperlipidemia, obesity, prediabetes or diabetes, or depression; * be willing to share medical record data about healthcare use (30-day hospital readmissions and er, urgent care, primary care, and specialty care visits); * allow researchers to share information with the patient's primary care provider exclusion criteria: * require an interpreter * report no current psychotic disorder that would prevent participation * have no acute medical problem requiring immediate hospitalization * not report impairments preventing use of a computer or tablet (e.g. blind, deaf)

Keywords: voice-activated "smart" technology older adults
mothers' own milk optimization for preterm infants project (momo pip) pilot study

Conditions: Vitamin D Deficiency; Nutritional Deficiency

Summary: the overall goal of this study is to assess maternal vitamin d status along with diet, and milk composition, and in turn, to evaluate if infant vitamin d status can be improved with increased maternal supplementation and diet education. the central hypothesis is that by maximizing maternal vitamin d status in breastfed, preterm infants (\<35 weeks), there will be an increase infant 25(oh)d status at 1,2, and 3 months of age.


Eligibility criteria:
inclusion criteria: * women with documentation of fully breastfeeding who present within one month of delivery, who are 18-45 years old and in good general health will be eligible for participation. * infants \<35 weeks corrected gestational age at birth exclusion criteria: * no dmi/dmii, htn, or parathyroid disease if thyroid issues, currently euthyroid * multiple gestations * no liver disease * no major congenital abnormalities * no kidney disease * no inborn errors of metabolism * no parathyroid disease * no disorders of calcium metabolism * no antiepileptics * no steroids * no congenital heart disease * no severe illness at birth deemed incompatible with survival

Keywords: vitamin d
three regimens of ketamine infusion in complex regional pain syndrome

Conditions: Ketamine Infusion; Complex Regional Pain Syndromes

Summary: to evaluate the efficacy of three regimens of sub anesthetic dose of ketamine infusion in relieving chronic refractory pain in patients with complex regional pain syndrome

ketamine n-methyl-d-aspartate (nmda) receptor blocker that has recently been studied for its analgesic effect is a phencyclidine or phenyl cyclohexyl piperidine (pcp) derivative that initially became commercially available for human use in 1970 as a rapid-acting intravenous (iv) anesthetic. it is currently classified by the food and drug administration (fda) as an anesthetic induction agent in doses ranging from 1 to 4.5 mg/kg. ketamine has proven to be a desirable drug, despite of its induction dissociative effects and abuse potential. it is favorable due to its short half-life and lack of clinically significant respiratory depression. in addition to its anesthetic effects, ketamine has analgesic, anti-inflammatory, and antidepressant activities.

Eligibility criteria:
inclusion criteria: * patients aged more than 21 years old of both sexes with american standards association i ,ii. * patients diagnosed as ( crps) based on budapest criteria * the average daily pain intensity required on (nrs) is 7 or more for at least 3 months despite of standard therapy which includes: (pharmacologic therapy as non steroidal anti- inflammatory drugs (nsaids), antiepileptic (aeds), antidepressants), as well as physical therapy and psychiatric care exclusion criteria: * patients refusal * patients with unstable psychological or psychiatric conditions, including : untreated bipolar disorder, post-traumatic stress disorder, major depression , severe personality disorder and psychotic illness. * patients have recently undergone major interventional pain procedures, such as nerve blocks or implantable therapies within 3 months of enrollment. * patients with known drug dependency or substance use disorder specifically related to ketamine or other psycho-stimulant drugs. * patients with previous severe reactions, contraindication or allergy to ketamine. * patients with cardiovascular disease (hypertension, arrhythmia), hepatic, renal or other organ impairment.
fatty liver response of cardio-metabolic risk factors to laser acupuncture versus cupping

Conditions: Fatty Liver

Summary: every-two-week applied cupping (with scarification) session within one month on back of upper thorax is not compared previously regarding its effect on cardio-metabolic risk factors to the daily application of laser on acupoints (for month, except fridays) in fatty liver patients. this trial will compare the two procedure effects on cardio-metabolic risk factors in fatty liver.

in fatty liver patients,every-two-week applied cupping (with scarification) session within one month on back of upper thorax for 30 patients will be compared regarding its effect on cardio-metabolic risk factors to the daily application of laser on acupoints (for month, except fridays) of other 30 patients.

Eligibility criteria:
inclusion criteria: * diagnosed fatty liver patients by ultrasonography * class i obese patients exclusion criteria: * cardiovascular and respiratory disorders/diseases. * autoimmune disorders/diseases. * pregnancy * other liver disorders/diseases.
stildep: zolpidem in depressive and dysthimic patients

Conditions: Sleep Initiation and Maintenance Disorders; Depression

Summary: primary objective: to show that the combination of zolpidem + antidepressant therapy is more effective in the treatment of the secondary insomnia of depressive and dysthimic patients than antidepressant therapy alone in the acute phase of the disease.


Eligibility criteria:
inclusion criteria: * depressive and dysthimic patients in acute phase of mild to moderate severity * depressive and dysthimic patients suffering from secondary insomnia (dsm iv) recent antidepressant therapy (less than 1 week) exclusion criteria: * regularly use of sleeping pills in the last 2-3 month * use of any sleeping pils in the last week * insufficient hepatic * myasthenia gravis * proven hypersensivity to zolpidem * evidence of clinically relevant nervous system disorders (other neurologic/psychiatric diseases associated with depression) * history of evidence of alcohol or drug abuse * evidence of clinically relevant cardiovascular, haematologic, hepatic, gastrointestinal, renal, pulmonary or endocrinologic diseases * abnormal snore * work an alternating shift * suffering from periodic leg movement disorder and sleep apnea
intervention for male stds in india

Conditions: Sexually Transmitted Infection

Summary: the specific aim of this study is to complete an ongoing randomized controlled trial of the efficacy of behavioral intervention compared to sti treatment/hiv counseling alone in decreasing risk behavior and incident hiv/sti infections in mumbai, india.

india has the second highest number of hiv infections of any country in the world, and the epidemic continues unabated. this trial is focused on high risk men attending public sti clinics. a proposed 2 and a half year study, this trial will utilize the continuation of a randomized controlled trial of a behavioral intervention compared to hiv c\&t and sti treatment alone targeting hiv uninfected male sti patients. the specific aims are to complete the current behavioral intervention trial and to expand the current investigations to include: the evaluation of men who have sex with men as well as women and evaluate the use of alcohol to the entire sample of recruited men. sti patients will be recruited from three sites and if randomized will agree to a 12 month participation commitment. strategies employed in both arms of the trial are simple and the fundamental components of an hiv prevention strategy. by demonstrating their effectiveness in india the hope is to encourage the public health leadership to adopt them and continue to change drug treatment availability.

Eligibility criteria:
inclusion criteria: 1. males, over 16 years of age 2. hindu or marathi speakers 3. have no plan to move permanently out of mumbia in the following 12 months 4. have a symptom of an sti or have had a sexual exposure in the past 6 months. a sexual exposure is defined as having sex with a commercial sex worker (fsw), having unprotected sex with anyone, male or female, or if the patient came to the clinic seeking an hiv test. 5. patients will be required to provide an address that can be located by a tracer. exclusion criteria: 1. hiv positive subjects.

Keywords: india, male, sexually transmitted infection, sti, std
metagenomic sequencing in clinical infectious diseases

Conditions: Bacterial Infections and Mycoses

Summary: progress in the diagnosis of infectious pathogens depends on the development of effective methods and the discovery of suitable biomarkers. there are several kinds of methods that have been used in diagnosis of various pathogens, such as microscopic examination, culture, serologic diagnosis or molecular approaches, etc. however, these methods have similar limitations, that is, the single detection of reagents. more importantly, physicians seldom consider infections with rare pathogens. recently developed metagenomic next-generation sequencing (mngs) has the capability to overcome limitations of traditional diagnostic tests. this new technology could identify all pathogens directly from sample with a single run in a hypothesis-free and culture-independent manner. studies have shown that mngs is more sensitive than traditional culture method in clinical conditions such as blood stream, respiratory and general infections. more importantly, due to unbiased sampling, mngs is theoretically able to identify not only known but also unexpected pathogens or even discovery novel organisms. it should be noted that mngs also has some limitations such as human genome contamination and possibly environmental microbial contamination. the vast majority of reads in mngs are derived from human host. this would impede the overall analytical sensitivity of mngs for pathogen detection. host depletion methods or targeted sequencing may help to partially mitigate this disadvantage. as mngs could not, by itself, define whether the detected microbe is the causative pathogen or environmental microorganism, a multidisciplinary discussion by clinicians, microbiologists as well as the lab technicians is required to interpret the result.


Eligibility criteria:
inclusion criteria: * all the patients have received mngs testing in clinical practice. exclusion criteria: * interruption of patient treatment process and incomplete information

Keywords: clinical metagenomics; infection diseases
radiation therapy and intratumoral autologous dendritic cells in soft tissue sarcomas (sts)

Conditions: Soft Tissue Sarcoma

Summary: the purpose of this study is to determine if injection of the participant's our own immune related white blood cells (called dendritic cells) into their tumor will strengthen their immune system to fight against their cancer.


Eligibility criteria:
inclusion criteria: * intermediate or high grade (ajcc 7th edition grade 3 and 4 or grade 2 and 3 of a 3 tier system) sts as determined by local pathology diagnostic biopsy specimen review * musculoskeletal tumor in extremities, trunk or chest wall * primary tumor or isolated locally recurrent tumor greater than 5 cm in diameter as measured by response evaluation criteria in solid tumors (recist) criteria v1.1 * clinical stage t2n0m0 (ajcc 7th edition) * age ≥18 years at time of consent * eastern cooperative oncology group (ecog)/zubrod performance status of 0 or 1 * patient's written study specific, institutional review board (irb) stamped informed consent. * adequate organ function (measured within a week prior to beginning treatment for arm b and within 2 weeks of beginning treatment for arm a): white blood count (wbc) \> 3,000/mm³ and absolute neutrophil count (anc) \>1500/mm³; platelets \> 100,000/mm³; hematocrit \> 25%; bilirubin \ 60 ml/min * radiation oncologist must confirm that a 2-3 cm strip of skin can be spared from rt. exclusion criteria: * retroperitoneal or head and neck primary locations * gastrointestinal stromal tumor (gist) * demonstrated metastatic disease * contraindication to resection * prior rt if the current tumor is locally recurrent after prior resection * concurrent treatment with any anticancer agent other than rt as dictated by the protocol * prior chemotherapy for the pre-surgical treatment of the primary tumor (neoadjuvant chemotherapy)bleeding/coagulation disorder * human immunodeficiency virus (hiv) infection or other primary immunodeficiency disorder * ongoing systemic therapy with immunosuppressant drugs (e.g. corticosteroids, azathioprine, cyclosporin, methotrexate) * steroid therapy within 4 weeks of first dc administration * any serious ongoing infection * pregnant or lactating women. patients in reproductive age must agree to use contraceptive methods for the duration of the study (\*a pregnancy test will be obtained before treatment).

Keywords: radiation neoadjuvant intratumoral autologous dendritic cells
interstitial lung disease registry study: prospective and retrospective observational study in austria

Conditions: Interstitial Lung Disease

Summary: the goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death. there are no additional interventions regarding this registry.


Eligibility criteria:
inclusion criteria: * diagnosis of interstitial lung disease * written informed consent exclusion criteria: * to not comprehend and rightfully judge participation
stem cells and tibial fractures

Conditions: Tibial Fractures

Summary: the aim of this trial is to determine the safety and tolerability of expanded autologous progeny of an adult cd34+ (haemopoietic) stem cell subset when infused directly into the tibial artery of patients with recent tibial fracture. the trial will also seek to determine clinical improvement or deterioration by measurement of clinical parameters such as, length of time to union of the fracture, changes in bone mineral density, improvements in pain scores (vas), functional ability (tugt) and ipaq scores.


Eligibility criteria:
inclusion criteria: * confirmed closed tibial fracture on one limb only * normal blood count * normal coagulation screen * life expectancy of at least 12 months * ability to give written informed consent exclusion criteria: * patients with additional lower limb injuries * patients with abnormal lower limb vasculature * pregnant or lactating women * unexplained abnormal baseline laboratory results * males and females who are capable of reproduction and will not take acceptable measures to prevent reproduction during the study * subjects who test positive for htlv, hiv, hepatitis b or hepatitis c, have a chronic inflammatory disease, autoimmune disease or are on chronic immunosuppressive medications * history of alcohol or drug abuse within 3 months of screening * subjects with evidence (clinical, laboratory, or imaging) of cancer or cancer recurrence within the past 5 years (other than non-melanoma skin cancer or in situ cervical carcinoma) * currently enrolled in another investigational device or drug trial that has not completed the required follow-up period * patients unable to give written informed consent

Keywords: fracture tibia stem cell
a phase i study to investigate the adme of kd101

Conditions: Obesity

Summary: a phase i study to investigate the absorption, metabolism, and excretion of kd101 in male subjects

a phase i study to investigate the absorption, metabolism, and excretion of kd101 in male subjects

Eligibility criteria:
inclusion criteria: * are able to provide written informed consent * the subject is a healthy korean aged 20 to 55 years, inclusive. * the subject weighs at least 55 and has a body mass index (bmi)over 27 exclusion criteria: * subjects with evidence or a history of clinically significant pulmonary, cardiovascular, hepatic, endocrine, hematological, neurologic or psychiatric diseases. * subjects with evidence of gastrointestinal disease which can affect the absorption of drug. * subjects with a history of drug abuse or a positive result in the urine drug screening for drug abuse * subjects who have taken any prescribed medicine or herbal medicine within 2 weeks before the first administration of the investigational product, any non-prescribed medicine or vitamin supplement within 1 week prior the first administration of the investigational product (if all other conditions are satisfied, subjects may be eligible for the trial as judged by the investigator.) * subjects who have donated a unit of whole blood within 30 days or who have participated in any other clinical trial within 60 days prior the first administration of the investigational product * subject who have history of allergy. * subject who can not continue proper contraception method during study period. * subjects who consume more than 21 units of alcohol per week (1 unit = 10 g of pure alcohol) or who are unable to abstain from drinking during the pk/pd testing period * subjects who are unable to abstain from smoking during the pk/pd testing period * subjects who are unable to abstain from grapefruit or caffeine containing food 1 day prior the first administration of the investigational product * subjects judged not eligible for the study after reviewing the clinical laboratory results or other reasons by the investigator.
allogeneic mesenchymal stem cells for osteoarthritis

Conditions: Osteoarthritis of Knee Joint

Summary: this study is designed to know the safety and efficacy of 2 different doses of mesenchymal stem cells in patients suffering from osteoarthritis of knee joint.


Eligibility criteria:
inclusion criteria: 1. males or females in the age 20 - 70 years (both inclusive) 2. radiographic evidence of grade 2 to 3 osteoarthritis based on the kellgren and lawrence radiographic entry criteria. 3. history of primary idiopathic osteoarthritis of the knee characterized by pain which requires intake of analgesics. 4. self-reported difficulty in at least one of the following activities attributed to knee pain: lifting and carrying groceries, walking 400 metres, getting in and out of a chair, or going up and down stairs. 5. patients who have been on stable medication for the past three months. 6. patients who have not received intra articular steroids or hyaluronan within the last three months. 7. female patients of childbearing age must be willing to use accepted methods of contraception during the course of the study 8. ability to provide written informed consent. exclusion criteria: 1. prior or ongoing medical conditions (e.g., concomitant illness, psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ecg findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results. 2. history of surgery, including arthroscopy, or major trauma to the study joint in the previous 12 months 3. signs of active study joint inflammation including redness, warmth, and/or, if qualifying with osteoarthritis of the knee, a large, bulging effusion of the study knee joint with the loss of normal contour of the joint at the screening visit or at the baseline examination 4. infections in or around the knee. 5. patients awaiting a replacement knee or hip joint 6. patients with other conditions that cause pain 7. significantly incapacitated or disabled and would be categorized as acr functional class iv (largely or wholly incapacitated), or unable to walk without assistive devices 8. patients with other known rheumatic or inflammatory disease such as rheumatoid arthritis 9. other pathologic lesions on x-rays of knee 10. positive hepatitis b surface antigen, hepatitis c antibody test, anti human immunodeficiency virus (hiv) antibody test, or vdrl 11. history of bleeding disorders 12. known hypersensitivity to hyaluronan products or animal sera 13. for women of child-bearing potential: positive pregnancy test or lactating

Keywords: osteoarthritis knee stem cell msc
effects of a beverage rich in fruit extracts on risk factors associated with cardiovascular disease

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to assess the effects of a novel beverage rich in polyphenols (compounds present in fruit extracts) on risk factors associated with cardiovascular disease.

this study will assess the potential of a beverage containing plant and fruit extracts rich in polyphenolics to modulate vascular risk. novel risk factors for vascular disease will be assessed including non-invasive assessment of vascular function by pulse wave analysis / pulse wave velocity and laser doppler iontophoresis.

Eligibility criteria:
inclusion criteria: * age \>/= 55 years * bmi \> 25 exclusion criteria: * present smoker or smoked within the last 2 years * hba1c \> 6.0% * egfr\<60 * lft \>/= 3 times upper limit of normal * hypertension: systolic blood pressure \> 160mmhg; diastolic blood pressure \> 90mmhg, or on medication for hypertension. * chronic disease, likely to be clinically relevant (eg: cardiorespiratory, rheumatological, cerebrovascular or neoplastic disease) * vitamin supplements within the previous 14 days * medications which, in the opinion of the investigators, are known to influence vascular function (eg corticosteroids).

Keywords: polyphenolics flavonols lipids endothelial function vascular risk factors